Ajanta Pharma USA Inc.

I'll research this company before writing the profile.

Let me verify the tracked case and the US generics business details.

Ajanta Pharma USA Inc. is the U.S. subsidiary of Ajanta Pharma Limited (NSE: AJANTPHARM; BSE: 532331), an India-based specialty pharmaceutical company founded in 1973 and headquartered in Mumbai. The parent is publicly listed and employs roughly 9,600–10,400 people, with reported consolidated revenue of about ₹46 billion in FY2025. Ajanta Pharma USA Inc. is a wholly owned, non-listed subsidiary based in Bridgewater, New Jersey.

The U.S. entity handles sales, marketing and distribution of generic drugs in the American market. Its parent develops and manufactures specialty pharmaceutical finished dosages — tablets, capsules, injectables, inhalers, ophthalmology drops, creams and ointments — across cardiology, dermatology, ophthalmology, pain management, gynaecology, nephrology and anti-malarial/antibiotic therapies. The business comprises branded generics in India, Asia and Africa, a U.S. generics arm, and an institutional business in Africa. The U.S. arm is an ANDA filer focused largely on oral solids; the parent reported 49 commercialized ANDAs and roughly 19 more awaiting FDA approval as of FY2026.

Litigation posture: This is an operating company, not a patent assertion entity. The structured data show 0 cases as plaintiff and 1 as defendant — the expected profile of a generic manufacturer defending Hatch-Waxman paragraph IV challenges. There is no plaintiff-side assertion activity.

Notable case: Merck Sharp & Dohme Corp. v. Ajanta Pharma Limited et al., No. 1:20-cv-01496 (D. Del., filed Nov. 2020), an ANDA patent-infringement suit naming both Ajanta Pharma Limited and Ajanta Pharma USA Inc. It was coordinated with Merck's multi-defendant Delaware litigation (19-md-02902) before Judge Richard G. Andrews and terminated by consent judgment on September 15, 2021. The asserted patent, U.S. 7,326,708, relates to Merck's sitagliptin phosphate diabetes product. Venue was the District of Delaware, the standard forum for such ANDA suits, not a plaintiff-friendly NPE venue.